Published in Cardiol Rev on December 22, 2005
Registry and Survey of Women With Pregnancy Related Cardiomyopathy | NCT00273637
The cell biology of disease: cellular mechanisms of cardiomyopathy. J Cell Biol (2011) 1.54
Fetal cells traffic to injured maternal myocardium and undergo cardiac differentiation. Circ Res (2011) 1.45
Clinical review: Special populations--critical illness and pregnancy. Crit Care (2011) 1.20
Case report and mini literature review: anesthetic management for severe peripartum cardiomyopathy complicated with preeclampsia using sufetanil in combined spinal epidural anesthesia. Yonsei Med J (2011) 1.06
Peripartum cardiomyopathy: review of the literature. Yonsei Med J (2007) 0.98
Peripartum cardiomyopathy: current state of knowledge, new developments and future directions. Curr Cardiol Rev (2014) 0.85
Combined epidural anesthesia and ultrasound guided peripheral nerve block for wound revision in a patient with peripartum cardiomyopathy -A case report-. Korean J Anesthesiol (2010) 0.75
Peripartum cardiomyopathy. Ann Med Health Sci Res (2013) 0.75
Peri-partum cardiomyopathy in a pregnant woman at term revealed by acute pulmonary edema: what to do in front this catastrophic situation? Pan Afr Med J (2014) 0.75
Comparison of self-report, hospital discharge codes, and adjudication of cardiovascular events in the Women's Health Initiative. Am J Epidemiol (2004) 3.53
ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation (2011) 1.97
Angiotensin receptor blockers for management of hypertension. South Med J (2010) 1.54
A bridge too far: a critique of the new ACGME duty hour requirements. Am J Med (2012) 1.46
Aldosterone and aldosterone antagonism in cardiovascular disease: focus on eplerenone (Inspra). Heart Dis (2003) 1.45
Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis. Cardiol Rev (2010) 1.35
Intravascular device infections: epidemiology, diagnosis, and management. Cardiol Rev (2006) 1.30
Estrogen and progestin use and the QT interval in postmenopausal women. Ann Noninvasive Electrocardiol (2004) 1.27
Pathophysiology, diagnosis, and treatment of orthostatic hypotension and vasovagal syncope. Cardiol Rev (2007) 1.17
ST-elevation myocardial infarction in the elderly--temporal trends in incidence, utilization of percutaneous coronary intervention and outcomes in the United States. Int J Cardiol (2013) 1.16
Inflammation and atherosclerosis: a review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy. Cardiol Rev (2014) 1.15
Cardiovascular complications of eating disorders. Cardiol Rev (2006) 1.15
Cardiovascular drug therapy in the elderly: benefits and challenges. Nat Rev Cardiol (2010) 1.13
Neuropsychiatric effects of cardiovascular drug therapy. Cardiol Rev (2003) 1.12
Treatment of hypertension and prevention of ischemic stroke. Curr Cardiol Rep (2004) 1.11
Vascular Ehlers-Danlos syndrome: pathophysiology, diagnosis, and prevention and treatment of its complications. Cardiol Rev (2011) 1.09
Myocardial regeneration and stem cell repair. Curr Probl Cardiol (2008) 1.08
Operationalizing the internal medicine milestones-an early status report. J Grad Med Educ (2013) 1.07
Trends in incidence, management, and outcomes of cardiogenic shock complicating ST-elevation myocardial infarction in the United States. J Am Heart Assoc (2014) 1.06
Protein kinase C in cardiac disease and as a potential therapeutic target. Cardiol Rev (2004) 1.06
Targeting heme oxygenase: therapeutic implications for diseases of the cardiovascular system. Cardiol Rev (2009) 1.04
Pharmacologic inhibition of squalene synthase and other downstream enzymes of the cholesterol synthesis pathway: a new therapeutic approach to treatment of hypercholesterolemia. Cardiol Rev (2009) 1.04
Association of ankle-brachial index with severity of angiographic coronary artery disease in patients with peripheral arterial disease and coronary artery disease. Cardiology (2005) 1.03
Carcinoid heart disease. Cardiol Rev (2012) 1.03
U.S. medical students' perceptions of the adequacy of their schools' curricular attention to care at the end of life: 1998-2006. J Palliat Med (2008) 1.01
Cardiac and pericardial tumors. Cardiol Rev (2012) 1.01
Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease. Cardiol Rev (2007) 1.00
HDL metabolism and CETP inhibition. Cardiol Rev (2008) 1.00
A national survey of cardiovascular physicians' beliefs and clinical care practices when diagnosing and treating depression in patients with cardiovascular disease. Cardiol Rev (2006) 0.99
Cardiac amyloidosis: approaches to diagnosis and management. Cardiol Rev (2009) 0.99
Endothelin as a clinical target in the treatment of systemic hypertension. Cardiol Rev (2009) 0.98
Experience with faculty supervision of an electronic resident sign-out system. Am J Med (2010) 0.98
Relation of baseline plasma ADMA levels to cardiovascular morbidity and mortality at two years in men with diabetes mellitus referred for coronary angiography. Atherosclerosis (2009) 0.98
Marijuana Use and Cardiovascular Disease. Cardiol Rev (2016) 0.97
Obesity: new perspectives and pharmacotherapies. Cardiol Rev (2006) 0.95
Pyrrolidine dithiocarbamate restores endothelial cell membrane integrity and attenuates monocrotaline-induced pulmonary artery hypertension. Am J Physiol Lung Cell Mol Physiol (2008) 0.95
Cardiac manifestations of sarcoidosis and therapeutic options. Cardiol Rev (2009) 0.94
Laughter-induced syncope. Cardiol Rev (2012) 0.93
Therapeutic angiogenesis: a new treatment approach for ischemic heart disease--part I. Cardiol Rev (2008) 0.93
A multidisciplinary approach for teaching systems-based practice to internal medicine residents. J Grad Med Educ (2011) 0.92
Phytoestrogens as cardioprotective agents. Cardiol Rev (2004) 0.91
Trends in acute kidney injury and outcomes after early percutaneous coronary intervention in patients ≥75 years of age with acute myocardial infarction. Am J Cardiol (2013) 0.90
Therapeutic angiogenesis: a new treatment approach for ischemic heart disease--Part II. Cardiol Rev (2008) 0.90
Compliance with National Cholesterol Education Program dietary and lifestyle guidelines among older women with self-reported hypercholesterolemia. The Women's Health Initiative. Am J Med (2002) 0.90
Cardiovascular pharmacotherapeutic considerations during pregnancy and lactation. Cardiol Rev (2004) 0.90
Risk factors for appropriate cardioverter-defibrillator shocks, inappropriate cardioverter-defibrillator shocks, and time to mortality in 549 patients with heart failure. Am J Cardiol (2010) 0.89
Valvular heart disease and systemic lupus erythematosus: therapeutic implications. Heart Dis (2003) 0.89
Allopurinol as a cardiovascular drug. Cardiol Rev (2011) 0.89
Cardiovascular pharmacotherapeutic considerations during pregnancy and lactation. Cardiol Rev (2004) 0.89
Role of magnesium in cardiovascular diseases. Cardiol Rev (2014) 0.89
Myotonic dystrophies and the heart. Cardiol Rev (2011) 0.88
Reducing hospital readmissions for cardiovascular disease: is it feasible? Am J Med (2013) 0.88
Brown adipose tissue thermogenesis: β3-adrenoreceptors as a potential target for the treatment of obesity in humans. Cardiol Rev (2013) 0.88
Remote patient monitoring in chronic heart failure. Cardiol Rev (2013) 0.88
Toll-like receptors: new therapeutic targets for the treatment of atherosclerosis, acute coronary syndromes, and myocardial failure. Cardiol Rev (2008) 0.88
Gender, ethnicity and genetics in cardiovascular disease: part 1: Basic principles. Heart Dis (2003) 0.87
Chronic renal dysfunction as an independent risk factor for the development of cardiovascular disease. Cardiol Rev (2005) 0.87
The emerging role of apelin in cardiovascular disease and health. Cardiol Rev (2009) 0.87
Urotensin II: a new pharmacologic target in the treatment of cardiovascular disease. Cardiol Rev (2008) 0.86
The cardiac ryanodine receptor (RyR2) and its role in heart disease. Cardiol Rev (2005) 0.86
Comprehensive management of hypertensive emergencies and urgencies. Heart Dis (2002) 0.86
Cardiovascular considerations in patients undergoing gastrointestinal endoscopy. Cardiol Rev (2008) 0.86
Cardiac involvement in hemochromatosis. Cardiol Rev (2014) 0.85
Neurologic and cardiac benefits of therapeutic hypothermia. Cardiol Rev (2011) 0.85
Cytokines and myocardial regeneration: a novel treatment option for acute myocardial infarction. Cardiol Rev (2008) 0.85
Direct inhibition of renin as a cardiovascular pharmacotherapy: focus on aliskiren. Cardiol Rev (2007) 0.85
Pharmacokinetics of propranolol after single and multiple dosing with sustained release propranolol or propranolol CR (innopran XL) , a new chronotherapeutic formulation. Heart Dis (2003) 0.85
Cardiovascular and respiratory considerations with pharmacotherapy of glaucoma and ocular hypertension. Cardiol Rev (2008) 0.84
Air pollution exposure as a risk factor for cardiovascular disease morbidity and mortality. Cardiol Rev (2013) 0.84
Alternative and complementary medicine for preventing and treating cardiovascular disease. Dis Mon (2009) 0.84
Lipoprotein-associated phospholipase A2: an independent predictor of cardiovascular risk and a novel target for immunomodulation therapy. Cardiol Rev (2009) 0.84
Cardiac manifestations of neonatal lupus: a review of autoantibody-associated congenital heart block and its impact in an adult population. Cardiol Rev (2012) 0.84
Fabry disease: cardiac manifestations and therapeutic options. Cardiol Rev (2008) 0.83
Chymase: a new pharmacologic target in cardiovascular disease. Cardiol Rev (2006) 0.83
Congestive heart failure and continuous positive airway pressure therapy: support of a new modality for improving the prognosis and survival of patients with advanced congestive heart failure. Heart Dis (2002) 0.83
Rho-kinase inhibition in the therapy of cardiovascular disease. Cardiol Rev (2005) 0.83
RESPeRATE: nonpharmacological treatment of hypertension. Cardiol Rev (2011) 0.82
Flavanol-rich cocoa: a cardioprotective nutraceutical. Cardiol Rev (2008) 0.82
The existence of myocardial repair: mechanistic insights and enhancements. Cardiol Rev (2013) 0.82
Vitamin D: a cardioprotective agent? Cardiol Rev (2011) 0.82
Predictors of in-hospital mortality and acute myocardial infarction in thrombotic thrombocytopenic purpura. Am J Med (2013) 0.82
Hypertension in Sub-Saharan Africa: A Contextual View of Patterns of Disease, Best Management, and Systems Issues. Cardiol Rev (2015) 0.82
Anemia and hypocholesterolemia. Heart Dis (2003) 0.81
Prevalence of appropriate cardioverter-defibrillator shocks in 1038 consecutive patients with implantable cardioverter-defibrillators. Am J Ther (2009) 0.81
Systemic hypertension: the roles of salt, vascular Na+/K+ ATPase and the endogenous glycosides, ouabain and marinobufagenin. Cardiol Rev (2012) 0.81
Variability of response to clopidogrel: possible mechanisms and clinical implications. Cardiol Rev (2006) 0.81
Vernakalant: a new drug to treat patients with acute onset atrial fibrillation. Cardiol Rev (2010) 0.81
A new approach to inotropic therapy in the treatment of heart failure: cardiac myosin activators in treatment of HF. Cardiol Rev (2013) 0.80
Testosterone and coronary artery disease. Cardiol Rev (2010) 0.80
Liver x receptors: a potential therapeutic target for modulating the atherosclerotic process. Cardiol Rev (2010) 0.80
Aspirin resistance: mechanisms and clinical implications. Cardiol Rev (2005) 0.80
Early invasive versus initial conservative treatment strategies in octogenarians with UA/NSTEMI. Am J Med (2013) 0.80
Elastinolytic matrix metalloproteinases and their inhibitors as therapeutic targets in atherosclerotic plaque instability. Cardiol Rev (2004) 0.80
Cardiovascular drug therapy in the elderly. Cardiol Rev (2007) 0.79
Sortilin: the mechanistic link between genes, cholesterol, and coronary artery disease. Cardiol Rev (2014) 0.79
Sirolimus-eluting coronary stents: novel devices for the management of coronary artery disease. Am J Ther (2004) 0.79
Incidence of appropriate cardioverter-defibrillator shocks and mortality in patients with implantable cardioverter-defibrillators with ischemic cardiomyopathy versus nonischemic cardiomyopathy at 33-month follow-up. Arch Med Sci (2010) 0.79
Renal sympathetic denervation for the treatment of systemic hypertension. Cardiol Rev (2012) 0.79